Tradipitant, sold under the brand name Nereus, is a medication used as prevention of vomiting induced by motion (motion sickness).[1] It is a neurokinin 1 receptor antagonist.[1] It works by blocking substance P, a small signaling molecule.[1] VLY-686 was purchased by Vanda Pharmaceuticals from Eli Lilly and Company in 2012.[2]
Tradipitant was approved for medical use in the United States in December 2025.[3]
Medical uses
Tradipitant is indicated for the prevention of vomiting induced by motion.[1]
Society and culture
Legal status
Tradipitant was approved for medical use in the United States in December 2025.[4]
Names
Tradipitant is the international nonproprietary name.[5]
Tradipitant is sold under the brand name Nereus.[1]
References
- 1 2 3 4 5 6 https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/220152Orig1s000lbl.pdf [bare URL PDF]
- ↑ "Company Overview of Eli Lilly & Co., Worldwide License to Develop and Commercialize VLY-686". Bloomberg Business. Retrieved 16 November 2015.
- ↑ "Novel Drug Approvals for 2025". U.S. Food and Drug Administration (FDA). 2 January 2026. Retrieved 10 January 2026.
- ↑ "Vanda Pharmaceuticals Announces FDA Approval of Nereus (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness" (Press release). Vanda Pharmaceuticals. 30 December 2025. Retrieved 10 January 2026 – via PR Newswire.
- ↑ "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 73". WHO Drug Information. 29 (1). 2015. hdl:10665/331088.
External links
- "Tradipitant ( Code - C152707 )". EVS Explore.
- Clinical trial number NCT04327661 for "Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness" at ClinicalTrials.gov
- Clinical trial number NCT05903924 for "Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness" at ClinicalTrials.gov
